Gladstone Institutes

Four new sources of venture capital for biotechnology companies were announced during the first half of May with more than $1.7bn in fresh funding for start-ups and growing early-stage firms. Abingwor

Venture capital investment in the biopharmaceutical industry continues to be massive in terms of both the number of companies raising funds and the size of funding rounds despite the ongoing economic

South San Francisco startup Tenaya Therapeutics Inc. has ambitious plans to advance three drug development platforms for cardiovascular disease: cell therapy, gene therapy and small molecule precisi

Revolution Medicines Inc. has been on a roll during the past year after entering into a partnership with Sanofi to develop its SHP2 inhibitor, buying Warp Drive Bio Inc. to bolster its cancer dru